Serina Therapeutics, INC

Serina Therapeutics, Inc. has amended and restated the employment agreement for its CEO, Steve Ledger, detailing salary, bonus structure, and severance packages.

Serina Therapeutics announced the appointment of Farrell Simon, Pharm. D., to its Board of Directors, effective July 22, 2026, who will also serve on the Audit and Compensation Committees.

Serina Therapeutics shareholders approved a significant increase in authorized common stock and amendments to the 2024 Equity Incentive Plan at the 2026 Annual Meeting.

Serina Therapeutics announced first-quarter 2026 financial results, highlighting progress in its Phase 1b registrational study for SER-252 in Parkinson's disease and the successful closing of a $21.2 million private placement.

Serina Therapeutics announced the appointment of a new CTO, an increase in CEO compensation, and amendments to its corporate bylaws.

Serina Therapeutics reported full-year 2025 financial results, highlighted by FDA clearance for SER-252, initiation of its Phase 1b trial, and a private placement financing of up to $30 million.

Serina Therapeutics reports increased operating expenses and net loss for Q1 2026, but significant cash infusion from financing activities bolsters liquidity.

Serina Therapeutics reported increased losses and a clinical hold on its lead Parkinson's drug, raising substantial doubt about its ability to continue as a going concern.

Serina Therapeutics, a clinical-stage biotech, reported a significant net loss in Q2 2025, alongside a going concern warning, despite active capital raising and pipeline advancement.

Serina Therapeutics reports a net loss of $4.8 million for Q1 2025 and expresses substantial doubt about its ability to continue as a going concern.

Serina Therapeutics reports its Q3 2024 results, highlighting a net loss of $8.4 million and ongoing concerns about its ability to continue as a going concern.

Serina Therapeutics reports its second quarter 2024 results, which include the impact of a recent merger and highlight ongoing financial challenges.

Serina Therapeutics, Inc. filed an Amendment No. 1 to its 2025 Annual Report on Form 10-K to correct an inadvertently incorrect Auditor Consent and include new certifications from its principal executive and financial officers.

Serina Therapeutics, a clinical-stage biotechnology company, reported a significant increase in net losses for 2025, alongside ongoing concerns about its ability to continue as a going concern, despite advancing its lead Parkinson's disease candidate, SER-252, into Phase 1b clinical trials and securing new capital.

Serina Therapeutics completes a reverse merger, transitioning its focus to developing novel Parkinson's disease treatments using its POZ platform technology.

AgeX Therapeutics has detailed the issuance of post-merger warrants to its shareholders and provided updates on its planned merger with Serina Therapeutics.

Farrell Simon, a Director of Serina Therapeutics, Inc., received 30,500 shares of common stock on July 22, 2026.

Serina Therapeutics, Inc. reports a stock purchase by Director Stephen K. Brannan.

Director Karen J. Wilson of Serina Therapeutics, Inc. has reported the acquisition of common stock through multiple transactions.

Serina Therapeutics CEO Steven A. Ledger has acquired 10,100 shares of common stock in a series of transactions.

Serina Therapeutics, Inc. reports that SVP Srini Tenjarla acquired stock options for 85,558 shares.

Steven A. Ledger, CEO of Serina Therapeutics, Inc., acquired stock options for 380,825 shares, with vesting scheduled over four years.

Serina Therapeutics has scheduled its 2026 Annual Meeting for June 17, 2026, to address key capital structure, equity incentive, and governance proposals.

Serina Therapeutics, Inc. filed an amendment to its definitive proxy statement, clarifying details for a stockholder vote on issuing common stock related to convertible notes and warrants.

Serina Therapeutics, Inc. has filed its definitive proxy statement with the U.S. Securities and Exchange Commission.

Serina Therapeutics, Inc. is holding its Annual Meeting to elect directors, ratify auditors, and approve a significant common stock issuance tied to a $20 million convertible note and warrants to fund clinical trials.

Serina Therapeutics, Inc. has filed a definitive proxy statement with the SEC.

Serina Therapeutics is asking stockholders to approve an amendment to its 2024 Equity Incentive Plan to increase the share reserve and introduce an evergreen provision.

Serina Therapeutics files an amendment to its Form S-1 registration statement, covering the issuance and resale of common stock and warrants following its merger with AgeX Therapeutics.

Serina Therapeutics aims to raise capital through warrant exercises while registering shares for resale, following a merger and name change from AgeX Therapeutics.

Serina Therapeutics files for an offering of common stock and warrants to support its neurological disease and pain treatment programs.

Juvenescence Limited and its subsidiaries now beneficially own approximately 27.3% of Serina Therapeutics, Inc. following a recent private placement.